Ascendis Pharma (ASND) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ascendis Pharma A/S has entered into an agreement selling 3% of its net sales rights for YORVIPATH® in the U.S. to Royalty Pharma Development Funding, LLC for $150 million. The deal includes provisions for a buy-out option and will be incorporated into Ascendis Pharma’s annual report. This strategic move could potentially conclude by the end of 2029 or upon the achievement of certain revenue multipliers.
For further insights into ASND stock, check out TipRanks’ Stock Analysis page.